Cansino Biologics
Cansino Biologics Inc., commonly referred to as Cansino, is a prominent biopharmaceutical company headquartered in China (CN). Founded in 2009, the company has established itself as a leader in the development of innovative vaccines and biologics, with a strong focus on addressing global health challenges. Cansino operates primarily in the fields of vaccine research and development, particularly in the areas of infectious diseases and oncology. The company gained significant recognition for its pioneering work on the Ad5-nCoV vaccine, which was one of the first COVID-19 vaccines to receive emergency use authorisation. Cansino's unique adenoviral vector platform sets it apart in the industry, enabling rapid development and deployment of vaccines. With a robust pipeline and strategic partnerships, Cansino Biologics continues to solidify its position as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Cansino Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cansino Biologics's score of 37 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cansino Biologics's reported carbon emissions
In 2023, Cansino Biologics reported total greenhouse gas emissions of approximately 37,294,900 kg CO2e, with emissions distributed across various scopes: 3,372,900 kg CO2e from Scope 1, 14,064,580 kg CO2e from Scope 2, and 19,689,150 kg CO2e from Scope 3. This represents a significant increase from 2022, where total emissions were about 30,517,250 kg CO2e. Cansino Biologics has set ambitious reduction targets, aiming for a 40% reduction in total greenhouse gas emissions per floor area by 2025, using 2021 as the baseline. Furthermore, they plan to achieve a 50% reduction by 2030 for both Scope 1 and Scope 2 emissions. These commitments reflect the company's proactive approach to addressing climate change and reducing its carbon footprint. The emissions data is not cascaded from any parent organization, indicating that Cansino Biologics is independently reporting its emissions and climate commitments. The company is actively working towards its targets, demonstrating a commitment to sustainability in the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 4,609,750 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 10,386,950 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cansino Biologics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
